May 25, 2005 — The U.S. Food and Drug Administration and Serono, Inc., have notified healthcare professionals via letter of new information regarding the risks of cardiotoxicity and secondary acute ...
April 14, 2006 -- The US Food and Drug Administration (FDA) has approved first-time generic formulations of mitoxantrone HCl 2-mg/mL injection for the treatment of multiple sclerosis, prostate cancer, ...
The US Food and Drug Administration and Swiss biotechnology company, Serono, have amended the product label for the latter's multiple sclerosis drug, Novantrone (mitoxantrone), to highlight a risk of ...
A type of chemotherapy drug, called mitoxantrone, can potentially treat multiple sclerosis (MS) by suppressing blood cells that attack your myelin, the protective layer covering your brain and spinal ...
Learn everything you need to know about Mitoxantrone-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
Mitoxantrone hydrochloride was the first FDA-approved medication for both secondary-progressive multiple sclerosis (MS) and progressive-relapsing MS. It’s also used to treat relapsing-remitting MS ...
The recent approval in the US of Novartis' orally administered Gilenya (fingolimod) heralds a new phase in the treatment of Multiple Sclerosis (MS). Over the last few years, the MS market has been ...
Mitoxantrone (Novantrone, OSI) plus corticosteroids relieves pain, but does not prolong survival, of men with metastatic androgen-independent prostate cancer. Phase I/II studies have indicated that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback